Trial Profile
Phase II Trial of Abiraterone Acetate Combined With Dutasteride With Correlative Assessment of Tumor Androgen Levels and Androgen Receptor Sequence and Signaling at Baseline and at Progression
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 07 Nov 2021
Price :
$35
*
At a glance
- Drugs Abiraterone acetate (Primary) ; Dutasteride (Primary) ; Prednisone
- Indications Adenocarcinoma; Prostate cancer
- Focus Pharmacodynamics
- 18 May 2020 Results assessing whether methylation is associated with cancer progression in bone biopsies collected from patients with castration-resistant prostate cancer treated with abiraterone and dutasteride presented at the 115th Annual Meeting of the American Urological Association
- 16 Feb 2018 Status changed from active, no longer recruiting to completed.
- 12 May 2017 Planned End Date changed from 1 Jan 2017 to 1 Jan 2018.